An Integrated Model to Improve Medication Reconciliation in Oncology: Prospective Intervventional Study

Alessandro Passardi\textsuperscript{1}, MD; Patrizia Serra\textsuperscript{2}, BSc; Caterina Donati\textsuperscript{3}, BPharm; Federica Fiori\textsuperscript{4}, RN; Sabrina Prati\textsuperscript{4}, RN; Roberto Vespignani\textsuperscript{5}, BEng; Gabriele Taglioni\textsuperscript{6}, BPharm; Patrizia Farfaneti Ghetti\textsuperscript{7}, BPharm; Giovanni Martinelli\textsuperscript{8}, MD; Oriana Nanni\textsuperscript{2}, MStat; Mattia Altini\textsuperscript{9}, MD; Giovanni Luca Frassineti\textsuperscript{1}, MD; Martina Vittoria Minguzzi\textsuperscript{10}, MPharm

\textsuperscript{1}Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
\textsuperscript{2}Unit of Biostatistics and Clinical Trials, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
\textsuperscript{3}Oncology Pharmacy Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
\textsuperscript{4}Oncology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
\textsuperscript{5}IT Service, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
\textsuperscript{6}A.S.SO.FARM Community Pharmacy, Ravenna, Italy
\textsuperscript{7}Federfarma Community Pharmacy, Rimini, Italy
\textsuperscript{8}Hematology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy
\textsuperscript{9}Healthcare Administration, Azienda Unità Sanitaria Locale (AUSL) Romagna, Ravenna, Italy
\textsuperscript{10}Healthcare Administration, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy

Corresponding Author:
Roberto Vespignani, BEng
IT Service
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”
Via P. Maroncelli 40
Meldola, 47014
Italy
Phone: 39 0543 739992
Fax: 39 0543 739151
Email: roberto.vespignani@irst.emr.it

Abstract

\textbf{Background:} Accurate medication reconciliation reduces the risk of drug incompatibilities and adverse events that can occur during transitions in care. Community pharmacies (CPs) are a crucial part of the health care system and could be involved in collecting essential information on conventional and supplementary drugs used at home.

\textbf{Objective:} The aim of this paper was to establish an alliance between our cancer institute, Istituto Romagnolo per lo Studio dei Tumori (IRST), and CPs, the latter entrusted with the completion of a pharmacological recognition survey. We also aimed to integrate the national information technology (IT) platform of CPs with the electronic medical records of IRST.

\textbf{Methods:} Cancer patients undergoing antiblastic treatments were invited to select a CP taking part in the study and to complete the pharmacological recognition step. The information collected by the pharmacist was sent to the electronic medical records of IRST through the new IT platform, after which the oncologist performed the reconciliation process.

\textbf{Results:} A total of 66 CPs completed surveys for 134 patients. An average of 5.9 drugs per patient was used at home, with 12 or more used in the most advanced age groups. Moreover, 60\% (80/134) of the patients used nonconventional products or critical foods. Some potential interactions between nonconventional medications and cancer treatments were reported.

\textbf{Conclusions:} In the PROF-1 (Progetto di Rete in Oncologia con le Farmacie di comunità della Romagna) study, an alliance was created between our cancer center and CPs to improve medication reconciliation, and a new integrated IT platform was validated.

\textbf{Trial Registration:} ClinicalTrials.gov NCT04796142; https://clinicaltrials.gov/ct2/show/NCT04796142

\textit{(J Med Internet Res 2021;23(12):e31321) doi: 10.2196/31321}
medication recognition; medication reconciliation; IT platform; community pharmacies; healthcare transitions; pharmacy; oncology; drug incompatibility; information technology; drug interactions

Introduction

Medication reconciliation is the process of drawing up a complete and accurate list of all medications being taken by an individual patient, including drug name, dosage, frequency, and route of administration, and comparing them with the medications listed in the patient’s medical records or medication prescriptions. The aim of reconciliation is to reduce the risk of errors of omission, duplication, incorrect doses or timing, and adverse drug-drug or drug-disease interactions [1-3]. The Joint Commission on Accreditation of Health Care Organizations added the concept of reconciliation across the continuum of care as a national patient safety goal [4]. It has also been defined as one of the best strategies for maintaining the quality of care by the Agency for Healthcare Research and Quality [5] and is one of the 5 elements in the “High 5s Project” launched by the World Health Organization [6].

Reconciliation must be periodically performed at both the hospital and territorial level [7] and at every transition of care [8], especially when new medications are prescribed or rewritten as several professionals may be involved. The efficacy and quality of this process depends mainly on a preliminary pharmacological survey (recognition step), which not only takes into account the medications prescribed to the patient, but also the phytotherapeutic and homeopathic products, supplements, and foods taken, as well as any habit that might negatively affect patient safety [5]. The success of the recognition step depends on the interlocutor's ability to promote within the patient a sense of empowerment and responsibility in relation to treatment adherence [9]. The use of innovative drugs for the treatment of cancer is constantly increasing [10], and many are unknown to the vast majority of nonexperts in the field. This increases the risk of pharmacological discrepancies in the medications prescribed (or self-prescribed) in the interval between each access to the cancer center caring for the patient [11-13]. In particular, nonconventional medicinal and health preparations such as over-the-counter products, herbal medicines, and supplements are sources of potential pharmacological discrepancy and should be closely monitored [5]. Cancer patients frequently resort to such remedies in an attempt to improve their quality of life, often compromised by the side effects of the treatments, or to help them cope with the emotional aspects related to living with cancer.

Therapy errors have economic implications. The World Health Organization has estimated the cost of therapy errors to be at US $42 billion annually and has set a goal of reducing these costs (which are attributed to weaknesses in health care systems) by 50% within the next 5 years [14]. In the area of oncology, the extent of the economic risk is increased by the burden of expected outcomes and by the high costs of anticancer treatments for the UK National Health Service. In 2018, in Italy, these costs were estimated to be at €5659 million (US $6360 million), constituting the first item of public health expenditure and exceeding that of cardiovascular drugs [15].

Community pharmacies (CPs) are a crucial part of the health care system. They are neighborhood health care facilities whose activities include dispensing medications, treating minor ailments, and offering advice on well-being. CP staff also frequently build up a close relationship with their clients, and they are highly knowledgeable about food supplements as they are responsible for around 80% of the sales of these products on the market [16]. It is therefore relatively easy for CPs to gather information to obtain a complete and accurate picture of the use of conventional drugs and supplements at home.

The territory of Romagna has a population of 1,281,243, spread over 3 provinces (Forlì-Cesena, Ravenna, and Rimini), and represents 28.6% (366,436/1,281,243) of the Emilia-Romagna region in northern Italy. There are 356 CPs in Romagna. Our cancer institute (IRCCS Istituto Romagnolo per lo Studio dei Tumori [IRST]), “Dino Amadori”) is also based in this area. The center has a high level of computerization and standardization of all therapeutic, clinical, and experimental processes, guaranteeing maximum safety for patients and full traceability of the actions carried out by each professional, clinician, pharmacist, and nurse during their daily activities. The national association representing private CPs (Federfarmacia) recently developed an information technology (IT) platform (Dottorfarma) in collaboration with an e-commerce company (Promofarma) that can be used by CPs nationwide.

Given these premises, an alliance created between IRST and the CPs of Romagna seemed to provide the perfect opportunity [17] to improve the pharmacological reconciliation process and to bridge the “pharmaceutical gap” between the health care system and the patients. We carried out a prospective, interventional, nonpharmacological study of the first phase of the network project in oncology with the community pharmacies of Romagna (Progetto di Rete in Oncologia con le Farmacie di comunità della Romagna [PROF-1]) on a new model for medication reconciliation. Our overall aims were to create an organizational model and IT platform, assess their ability to promote the shared management of therapies by patients, pharmacists, and health care professionals (thus improving adherence to treatment and the home management of side effects), and evaluate the acceptability of this model by patients.

Methods

The team of investigators included the IRST oncology group (oncologists, hospital pharmacists, and nurses), IRST and Federfarmacia IT Services, CPs, and scientific representatives of private and public pharmacy associations. The study team also worked closely with lawyers from Federfarmacia and Promofarma to take care of the delicate aspects of professional responsibility and data privacy. During the feasibility analysis of the project (PROF-1 trial), the basic network model was defined by jointly identifying the individual professionals and their respective responsibilities. The investigators agreed that each of the professionals would be responsible for the accuracy of the
information provided, while the medication reconciliation process would be the exclusive responsibility of physicians. This decision meant that the data transmitted from a CP to IRST would only be valid after the clinician had downloaded, integrated, and confirmed the information. Regarding the CPs’ task of collecting patient data, it was agreed that the pharmacist transmitting data directly to IRST medical records would not be able to view or modify the entered information.

A drug recognition form was created and validated in a pilot study carried out on breast cancer patients [18]. The form was divided into 5 sections (medications, critical foods, supplements, phytotherapeutic products, and homeopathic products). Information would be gathered for each compound (eg, active ingredient and trade name; pharmaceutical form and route of administration; dosage, posology, start or end of intake, reason for intake, and prescriber). Initially conceived as a paper document, the form was digitized in both the Dottorfarma IT platform and IRST medical records for the purposes of the trial.

A total of 200 patients were considered for the PROF-1 study. A formal sample size calculation for this prospective study was not performed due to the lack of preliminary data and the exploratory intent of the study. Eligible patients were required to meet the following criteria: being adults ≥18 years old, of either gender; having an Eastern Cooperative Oncology Group performance status of ≤1; undergoing anticancer treatment; having a clear understanding of the Italian language; and granting written informed consent.

When the patients came to the institute for anticancer treatment, health care professionals provided information about the trial and obtained written informed consent from those willing to take part. The patients were asked to choose one of the CPs accredited for the trial and to book an appointment for the pharmacological recognition step. The accredited pharmacist, after ensuring that the patient had provided written informed consent and completed a privacy form, interviewed the patient in a private consultation area, completing the online drug recognition form in the Dottorfarma IT platform (Figure 1), which has the same format as that of IRST electronic medical records. The pharmacist took into account the information provided by the patient or delegated caregiver and that retrieved from drug packages or other products used by the patient at home (and brought to the interview), paper referrals, or prescriptions from specialists. The recognition data were sent to IRST through the Dottorfarma IT platform and automatically saved in a specific medical history file in the electronic medical records (Figure 2). Upon confirmation of the next course of chemotherapy, the oncologist downloaded the pharmacological recognition form and performed the reconciliation process. For the purposes of the present trial, the processes of recognition and reconciliation were carried out only once for each enrolled patient. Following the completion of the drug recognition and reconciliation processes, the patients were asked to complete a satisfaction questionnaire.

Descriptive statistical analyses were performed on all case series (absolute and relative frequency for categorical variables and median and quantiles for continuous variables). All statistical analyses were carried out using SAS Software, version 9.4 (SAS Institute).

This study was reviewed and approved by the AUSL (Azienda unità sanitaria locale) Romagna/IRST Ethics Committee (approval number 1722, October 26, 2016) and was conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and later versions. The participants provided written informed consent to take part in the study.

The data sets generated and analyzed during the current study are available from the corresponding author upon reasonable request.

Figure 1. Dottorfarma electronic scheme of the recognition form.
Figure 2. Drug history section of the IRST (Istituto Romagnolo per lo Studio dei Tumori) electronic medical records.

Results

A dialog between IRST and local CP associations was opened, leading to the creation of a specific agreement between the 2 parties. The first step involved the implementation of the Dottorfarma IT platform, initially with a one-way communication flow. The pharmacological recognition form was digitized on both the Dottorfarma IT platform and IRST electronic medical records, and the 2 systems were synchronized.

Pharmacy Recruitment and Training

Following an open invitation, out of 365, 120 (34%) of the public and private CPs of Romagna initially agreed to take part in the study. Pharmacy managers or a representative from each CP took part in a brief training course organized by IRST to inform the participants about the recognition and reconciliation process, to present the PROF-1 study, and to provide instructions on how to complete the pharmacological recognition form. A total of 108 CPs (84 private and 24 public CPs) finally agreed to participate in the trial (36 in the province of Forlì-Cesena, 26 in the province of Rimini, and 46 in the province of Ravenna). The enrolled patients chose 66 of these to complete the pharmacological recognition survey (Multimedia Appendix 1).

Patients

From April 2017 to April 2018, 200 patients were enrolled onto the trial. Among these, 137 (68.5%) underwent the pharmacological recognition interview as planned, while 63 (31.5%) were not evaluable, 39 (19.5%) withdrew consent, 11 (5.5%) were excluded for technical problems, and 13 (6.5%) spontaneously dropped out (Multimedia Appendix 1). Patient characteristics are shown in Table 1.

The majority of the patients were female (83, 61%), with a median age of 63 years. Most patients lived in the province of Forlì-Cesena, where our institute is based. The majority were undergoing chemotherapy (alone or in combination with targeted therapies), mainly administered intravenously. The list of anticancer drugs administered to the enrolled patients is reported in Table 2.

The analysis of the data entered by CPs revealed a total of 805 medications declared by the patients, with an average of 5.9 drugs per patient taken at home. As many as 12 or more medications were being taken by 6 patients over the age of 65 years. Drug distribution, identified in the recognition form according to the Anatomical Therapeutic Chemical classification, is reported in Table 3 (1st and 2nd levels).

Of the total 805 declared drugs, 29.4% (n=237) and 20.7% (n=167) were used to treat problems in the gastrointestinal and cardiovascular systems, respectively. The former drugs were mainly used to contrast chemotherapy side effects and cancer-related symptoms (eg, proton pump inhibitors and antacids, antiemetics, laxatives, and anti-diarrheals), while the latter mainly included antihypertensive drugs and statins. Drugs for the central nervous system represented 13.2% (n=106) of all drugs and comprised mainly analgesics and antidepressants or anxiolytics. Hormones (55, 6.8%), drugs for musculoskeletal disorders (47, 5.8%), antithrombotic or antianemic drugs (43, 5.3%) and systemic antimicrobials (32, 4%) were also being taken. Although the recognition of anticancer drugs was not required (this information was already present in the medical records), some patients reported oral anticancer drugs in their list of medicines. Further interesting information was obtained from the recognition form; ie, 87.6% (n=705) of drugs were taken orally. Moreover, sources of information varied, coming from medical documents (145, 18%), drug lists (227, 28.2%), product packages (86, 10.7%), patient declarations (270, 33.5%), and caregiver declarations (73, 9.1%). The main prescribers were specialist physicians (542, 67.3%) and general practitioners (204, 25.3%), while 1.5% (n=12) of the patients were self-prescribers.
Table 1. Patient characteristics (n=137).

| Variables                          | Values        |
|------------------------------------|---------------|
| Age (years), range (years)         | 67 (39-85)    |
| **Gender, n (%)**                  |               |
| Male                               | 54 (39)       |
| Female                             | 83 (61)       |
| **Provence of residence, n (%)**   |               |
| Forlì-Cesena                       | 86 (63)       |
| Ravenna                            | 36 (26)       |
| Rimini                             | 8 (6)         |
| Other                              | 7 (5)         |
| **Site of disease, n (%)**         |               |
| Gastrointestinal tract             | 36 (26)       |
| Breast                             | 31 (23)       |
| Genitourinary tract                | 27 (20)       |
| Hematologic malignancy             | 17 (12)       |
| Lung                               | 14 (10)       |
| **Anticancer treatment, n (%)**    |               |
| Chemotherapy                       | 55 (39)       |
| Chemotherapy plus targeted therapy | 28 (20)       |
| Targeted therapy                   | 21 (16)       |
| Immunotherapy                      | 13 (10)       |
| Hormonal therapy                   | 20 (15)       |
| **Administration route, n (%)**    |               |
| Intravenous                        | 74 (54)       |
| Intravenous and oral               | 33 (24)       |
| Oral                               | 30 (22)       |
Table 2. Anticancer drugs (n=462).

| Category and name of anticancer drugs | Values |
|---------------------------------------|--------|
| **Cytotoxic drugs, n (%)**            |        |
| Paclitaxel                            | 38 (8.2) |
| 5-fluorouracil                        | 36 (7.8) |
| Capecitabine                          | 36 (7.8) |
| Cyclophosphamide                      | 31 (6.7) |
| Gemcitabine                           | 30 (6.4) |
| Oxaliplatin                           | 29 (6.3) |
| Carboplatin                           | 25 (5.4) |
| Cisplatin                             | 23 (5.0) |
| Irinotecan                            | 18 (3.9) |
| Docetaxel                             | 17 (3.7) |
| Vinorelbine                           | 14 (3.0) |
| Doxorubicin                           | 13 (2.8) |
| Nab\(^a\)-paclitaxel                  | 11 (2.4) |
| Liposomal doxorubicin                 | 10 (2.2) |
| Epirubicin                            | 9 (1.9)  |
| Bendamustine                          | 8 (1.7)  |
| Eribulin                              | 7 (1.5)  |
| Etoposide                             | 7 (1.5)  |
| Melfalan                              | 7 (1.5)  |
| Trifluridine+tipiracil                | 6 (1.3)  |
| Pemetrexed                            | 5 (1.1)  |
| Total                                 | 380 (82.2) |
| **Targeted therapy n, (%)**           |        |
| Trastuzumab                           | 14 (3.0) |
| Rituximab                             | 11 (2.4) |
| Bevacizumab                           | 11 (2.4) |
| Cetuximab                             | 6 (1.3)  |
| Regorafenib                           | 7 (1.5)  |
| Total                                 | 49 (10.6) |
| **Immunotherapy n, (%)**              |        |
| Nivolumab                             | 13 (2.9) |
| **Hormonal therapy n, (%)**           |        |
| Fulvestrant                           | 9 (1.9)  |
| Abiraterone acetate                   | 6 (1.3)  |
| Enzalutamide                          | 5 (1.1)  |
| Total                                 | 20 (4.3) |

\(^a\)Nab: nanoparticle albumin-bound.
Table 3. Distribution of drugs (n=805) detected in the recognition (Anatomical Therapeutic Chemical, 1st and 2nd levels).

| ATC\(^a\) classification | Values                  |
|---------------------------|-------------------------|
| Gastrointestinal tract and metabolism, n (%) |                        |
| Proton pump inhibitors and antacids            | 82 (10.2)              |
| Antiemetics and prokinetics                     | 33 (4.1)               |
| Vitamin A and D and associations                | 30 (3.7)               |
| Insulin and hypoglycemic agents                 | 24 (3.0)               |
| Laxatives                                        | 18 (2.2)               |
| Antidiarrheal and anti-inflammatory intestinal  | 17 (2.1)               |
| Mineral supplements                              | 14 (1.7)               |
| Other                                            | 19 (2.3)               |
| Total                                            | 237 (29.4)             |
| Cardiovascular system, n (%)                    |                        |
| Antihypertensives (including diuretics)         | 128 (16.0)             |
| Statins                                          | 34 (4.2)               |
| Other                                            | 5 (0.6)                |
| Total                                            | 167 (20.7)             |
| Central nervous system, n (%)                   |                        |
| Analgesics (including opioids)                  | 53 (6.6)               |
| Antidepressants, anxiolytics, and sedatives      | 36 (4.5)               |
| Other                                            | 17 (2.1)               |
| Total                                            | 106 (13.2)             |
| Hormones (excluding insulin and sex hormones), n (%) |                     |
| Systemic corticosteroids                         | 42 (5.2)               |
| Thyroid preparations                             | 12 (1.5)               |
| Other                                            | 1 (0.1)                |
| Total                                            | 55 (6.8)               |
| Antineoplastic agents and immunomodulators, n (%) |                     |
| Oral anticancer drugs                            | 39 (4.8)               |
| Intramuscular hormonal antagonists               | 11 (1.4)               |
| Total                                            | 50 (6.2)               |
| Musculoskeletal system, n (%)                   |                        |
| Antigout drugs                                    | 23 (2.8)               |
| Anti-inflammatory drugs (including NSAIDs\(^b\)) | 16 (2.0)               |
| Bisphosphonates                                   | 6 (0.7)                |
| Other                                            | 2 (0.3)                |
| Total                                            | 47 (5.8)               |
| Blood and hematopoietic organs, n (%)            |                        |
| Antithrombotic drugs                             | 32 (4.0)               |
| Antianemic drugs                                  | 11 (1.3)               |
| Total                                            | 43 (5.3)               |
| Systemic antimicrobials, n (%)                   |                        |
| Antibacterials                                    | 22 (2.7)               |
### Table 3: ATC classification of medications

| ATC Classification                             | Values     |
|-----------------------------------------------|------------|
| Antivirals                                    | 9 (1.1)    |
| Antifungals                                   | 1 (0.1)    |
| Total                                         | 32 (4.0)   |
| Genitourinary tract and sex hormones, n (%)   | 20 (2.5)   |
| Respiratory system, n (%)                     | 18 (2.2)   |
| Skin, n (%)                                   | 7 (1.0)    |
| Other, n (%)                                  | 23 (2.9)   |

**ATC**: Anatomical Therapeutic Chemical.

In addition, of a total of 137 patients, 83 (60.5%) reported an intake of 201 nonconventional medications (supplements, phytotherapeutics, or homeopathic products), and 39 (28.5%) reported having taken foods considered critical for the potential interactions with medications (Table 4). A detailed analysis of the recognition form revealed that the most widely represented critical substances were coffee (23 patients, 16.8%), green tea (11 patients, 8%), aloe (6 patients, 4.4%), turmeric (5 patients, 3.6%), fermented red rice (5 patients, 3.6%), ginger (3 patients, 2.2%) and manna (3 patients, 2.2%).

An evaluation of drug-drug interaction was not carried out as it was not one of the aims of this paper. However, we investigated the potential for interaction between nonconventional products and cancer treatments (Table 4), identifying 2 possible interactions with aloe vera, 3 with manna, 1 with echinacea, 1 with ginseng, 2 with ginger, and 3 with red yeast rice. After analyzing the components present in the supplements taken by the patients but not present in our list of critical compounds, the following possible interactions emerged: 2 interactions with milk thistle, 2 with berberine, 1 with alpha lipoic acid, 1 with vitamin C, 1 with folic acid, and 1 with *Cordyceps sinensis*.

A total of 106 patients completed and returned the satisfaction questionnaire. Of these, 77 (72%) considered the reconciliation process as very important, 74 (70%) thought that the involvement of the pharmacist was very useful, and 87 (82%) reported no difficulty in going to the chosen pharmacy to complete the pharmacological recognition survey.
Table 4. Critical foods, nonconventional products, and potential interactions with cancer treatments.

| Product                     | Value  | Potential interaction                      |
|-----------------------------|--------|-------------------------------------------|
| **Critical foods, n (%)**   |        |                                           |
| Coffee                      | 23 (16.8) | _a                                       |
| Green tea                   | 11 (8) |                                           |
| Black tea                   |        |                                           |
| Bitter orange               |        |                                           |
| Carom                       |        |                                           |
| Grapefruit                  | 1 (0.7) | Regorafenib                               |
| Chili pepper                |        |                                           |
| Pepper                      |        |                                           |
| Turmeric                    | 5 (3.6) | Doxorubicin, cyclophosphamide             |
| **Phytotherapeutic, n (%)** |        |                                           |
| Aloe vera                   | 6 (4.4) | Paclitaxel, docetaxel                     |
| Charcoal                    |        |                                           |
| Echinacea                   | 1 (0.7) | Dexamethasone                             |
| Ginseng                     | 1 (0.7) | Etoposide                                 |
| Guarana                     |        |                                           |
| Hypericum                   |        |                                           |
| Red yeast rice              | 5 (3.6) | Cyclophosphamide, paclitaxel, etoposide   |
| Manna                       | 3 (2.2) | Capecitabine, enzalutamide, abiraterone   |
| Soy                         |        |                                           |
| Ginger                      | 3 (2.2) | 5-fluorouracil, capecitabine              |
| **Other compounds**, n (%)  |        |                                           |
| Milk thistle                | 2 (1.5) | Regorafenib, paclitaxel                  |
| Alpha-lipoic acid           | 1 (0.7) | Cisplatin                                 |
| Vitamin C                   | 1 (0.7) | Doxorubicin                               |
| Folic acid                  | 1 (0.7) | Capecitabine                              |
| Berberine                   | 2 (1.5) | Trastuzumab, vinorelbine                  |
| Cordyceps sinensis          | 1 (0.7) | Dexamethasone                             |

*a*Not applicable.

*b*Not reported in the official list of critical compounds, but with possible critical interactions in the post hoc analysis.

**Discussion**

**Principal Findings**

The PROF-1 trial achieved its goal of creating a new model for medication recognition and reconciliation processes in oncology thanks to the close cooperation between our institute and CPs, the implementation of an integrated IT platform, and the active participation of cancer patients.

An interest in being actively involved in the setting up of a new hospital territory network was clearly demonstrated by both public and private CPs in their willingness to take part, at no cost, in the project. A total of 120 CPs participated in the training course, and 108 agreed to enrol patients, the latter process involving a commitment of around 30 minutes for each survey to integrate into routine pharmacy activities. To the best of our knowledge, this was the first trial addressing the problem of medication reconciliation to include private entities not directly involved in the care of cancer patients.

PROF-1 confirmed the high number of medications used by patients at home (an average of 5.9 drugs per patient), especially in the most advanced age groups. Even more striking was the evidence of an increasing number of patients who used nonconventional products or critical foods. These results underline the importance of pharmacological recognition and reconciliation processes, which, despite being mandatory ministerial measures [1,3], are often neglected by oncologists because of the pressures of daily clinical activity. An alliance with CPs could thus lead to a significant improvement in the situation [19-21]. Numerous attempts have been made to
improve the medication reconciliation process, including pharmacist-related interventions and IT platforms, with interesting results in terms of reduction in medication discrepancies and potential adverse events [22]. However, none of the proposed models included the presence of community pharmacists.

Our study highlighted some limitations in this new model, the first concerning patient empowerment. Although the patients were personally involved and expressed a high degree of satisfaction through the questionnaire, a certain number who signed the informed consent did not go to the chosen CP to complete the recognition step. This may have been due to a deterioration in their clinical conditions or to the side effects of chemotherapy, given that the study population was recruited among those undergoing antibiotic therapy, regardless of prognosis or type of treatment. This is an important aspect to bear in mind as it suggests that some patients may not be suitable for this type of project. A review of the communication channels between patient and CP, including the use of the telephone or email rather than direct access, could perhaps improve this issue.

Another important limitation was that, given the exploratory nature of the trial, only one recognition-reconciliation process was planned for each patient, making it impossible to verify the advantage of a continuous exchange of information from a series of repeated processes to monitor changes in medications taken at home. A new trial (PROF-2) is ongoing to further implement and validate the model, this time incorporating the repetition of the recognition-reconciliation processes before each chemotherapy cycle. Another imitation concerns drug-drug interactions. As stated above, the use of a surprisingly high number of drugs, supplements, and nonconventional products were declared by patients, raising the question of possible interactions. However, we did not focus on the drug-drug interactions that emerged from the reconciliations performed by oncologists, as this was not an aim of the study. Conversely, our analysis of the potential interactions between cancer drugs and nonconventional products confirmed the importance of this issue. Finally, the difficult reproducibility of the proposed model must be emphasized as a possible limitation because of some basic requirements (ie, a high level of computerization of the centers taking part and the strict regulation of data processing and patient privacy). The strengths that made it possible to complete the project were the solidity of the computerized medical records present in our cancer institute, the presence of an IT platform that could be shared by all private and public CPs, and the approval of the project by the local ethics committee after in-depth teamwork to resolve the issues of professional responsibility, data ownership, and privacy management.

Based on the results from this pilot study, the alliance between the cancer center and the CPs of Romagna has led to the creation of a cancer network which, albeit initially established to meet a specific need, could help to systematically establish safety pathways for drugs used at home. This initiative could also contribute to increasing adherence to innovative drugs, essential not only for the success of treatment but also for the sustainability of the national health service of every nation. It could also improve the management of ancillary drugs for the prevention of toxicities, often underestimated or self-managed by patients [23]. The PROF-1 project was conceived and designed some years before the COVID-19 pandemic, which has forced the community to acknowledge the importance of the territory in the management of patients’ needs. Within this context, our model proved highly functional not only in terms of the study’s main aim (pharmacological reconciliation), but also in terms of the successful creation of a hospital community network whose impact may well exceed what was originally hypothesized.

Conclusions
The PROF-1 trial represents an important step forward in medication reconciliation in oncology. The alliance established between our cancer institute and local CPs to enhance medication reconciliation in transitions in care led to the creation of an innovative organizational model and the validation of a new integrated IT platform.

Acknowledgments
The authors wish to thank the late Professor Dino Amadori for his important contribution to the study design and for his support of this ambitious project from the very beginning. They also wish to thank all the patients who agreed to use the CPs (community pharmacy) involved in the study, thus contributing to the development of this experimental model; the CP pharmacists who took part in the project; Chiara Crispo and Andrea Tarozzi, Professor of Pharmacology at Bologna University, for their help with the analysis of drug interactions. Many authorities and professionals must be thanked for the support given to the project: the regional and provincial presidents of Federfarma in office at the start of the project and those currently in office (Daniele Raganato, Benedetta Camerani, Domenico Dal Re, Achille Gallina Toschi, Alberto Lattuneddu, Roberto Deluigi, and Pietro Guettinini); Ernesto Toschi, the regional president of Assofarm, and Barbara Pesci and Bruna Baldassarri of the Municipal Pharmacy Company of Ravenna; Bruno Foresti of Federfarma and Giulia Fatano of Promofarma; Giovanni Petrosillo and Daniele D’Angelo, former directors of Promofarma, and Claudio Montalto, IT engineer formerly at Promofarma; Marco Cossolo, president of the National Federfarma, Venanzio Gizzi, president of Assofarm, and Annarosa Racca, the former president of the National Federfarma; Susanna Ciampalini of the Quality Office of the General Directorate of Health Planning, and Ester Sapigni from the Drug Policy Service of the Emilia Romagna Region.

Authors’ Contributions
MVM, RV, and ON conceived the idea for and designed the study. MVM, AP, and RV collected patient data. AP, MVM, ON, PS, RV, CD, FF, SP, GT, PFG, GM, MA, and GLF were responsible for data interpretation. ON performed the statistical analyses.
References

1. Raccomandazione n. 17. Riconciliazione della terapia farmacologica. Ministry of Health of Italy. 2014 Dec. URL: https://www.salute.gov.it/imgs/C_17_pubblicazioni_2354_allegato.pdf [accessed 2021-12-09]

2. Regione Emilia Romagna. Sicurezza nella terapia farmacologica “Processo di ricognizione e di riconciliazione farmacologica per una prescrizione corretta e sicura”, Regione Emilia Romagna. 2015 Oct. URL: https://salute.regione.emilia-romagna.it/normativa-e-documentazione/rapporti/sicurezza-terapia-farmacologica/sicurezza_farmacologica_2_rev2015.pdf [accessed 2021-12-09]

3. Raccomandazione per la prevenzione degli errori in terapia con farmaci antineoplastici. Ministry of Health of Italy. 2012 Oct 14. URL: https://www.salute.gov.it/imgs/C_17_pubblicazioni_1861_allegato.pdf [accessed 2021-11-09]

4. No authors listed. Using Medication Reconciliation to Prevent Errors. The Joint Commission Journal on Quality and Patient Safety 2006 Apr;32(4):230-232. [doi: 10.1016/s1553-7250(06)32030-2] [Medline: 16649655]

5. Qato DM, Wilder J, Schumm LP, Gillet V, Alexander GC. Changes in Prescription and Over-the-Counter Medication and Dietary Supplement Use Among Older Adults in the United States, 2005 vs 2011. JAMA Intern Med 2016 Apr;176(4):473-482 [FREE Full text] [doi: 10.1001/jamainternmed.2015.8581] [Medline: 26998708]

6. The High 5s Project. Interim Report. World Health Organisation. 2013. URL: https://www.who.int/patientsafety/implementation/solutions/high5s/High5_InterimReport.pdf [accessed 2021-12-09]

7. Kwan JL, Lo L, Sampson M, Shojania KG. Medication reconciliation during transitions of care as a patient safety strategy: a systematic review. Ann Intern Med 2013 Mar 05;158(5 Pt 2):397-403 [FREE Full text] [doi: 10.7326/0003-4819-158-5-20130501-00006]

8. The High 5s Project. Standard Operating Protocol. Assuring Medication Accuracy at Transitions in Care. World Health Organisation. URL: https://www.who.int/patientsafety/implementation/solutions/high5s/h5s-sop.pdf [accessed 2021-12-09]

9. Daruwalla Z, Thakkar V, Aggarwal M, Kiasatdolatabadi A, Guergachi A, Keshavjee K. Patient Empowerment: The Role of Technology. Stud Health Technol Inform 2019;257:70-74. [Medline: 30741175]

10. Gobal Oncology Trends 2019. The IQVIA Institute. URL: https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2019 [accessed 2021-12-09]

11. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 2007 Apr 18;99(8):592-600. [doi: 10.1093/jnci/djk130] [Medline: 17440160]

12. Alqenae FA, Steinke D, Keers RN. Prevalence and Nature of Medication Errors and Medication-Related Harm Following Discharge from Hospital to Community Settings: A Systematic Review. Drug Saf 2020 Jun;43(6):517-537 [FREE Full text] [doi: 10.1007/s40264-020-00918-3] [Medline: 32125666]

13. Bonauo M, Martorana M, Dimonte V, D'Alfonso A, Fornero G, Politano G, et al. Medication discrepancies across multiple care transitions: A retrospective longitudinal cohort study in Italy. PLoS One 2018;13(1):e0191028 [FREE Full text] [doi: 10.1371/journal.pone.0191028]

14. Medication Without Harm. World Health Organization. 2017. URL: https://apps.who.int/iris/bitstream/handle/10665/255263/WHO-HIS-SDS-2017.6-eng.pdf;jsessionid=A93A39CC2B5A9DEEF2F43FFC0C2A70DB?sequence=1 [accessed 2021-12-09]

15. Monitoraggio della Spesa Farmaceutica Nazionale e Regionale Gennaio-Luglio 2020. Agenzia Italiana del Farmaco (AIFA). 2020 Dec 10. URL: https://www.aifa.gov.it/documents/20142/847405/Monitoraggio_Spesa_gennaio-luglio-2020.pdf/4170fed0-1430-dcfe-1e6c-53b7d6fa7592 [accessed 2022-12-09]

16. Rapporto Censis sul valore sociale dell’integrazione alimentare. Centro Studi Investimenti Sociali (CENIS). 2019. URL: https://www.federsalus.it/wp-content/uploads/2019/06/Rapporto-Censis-definitivo-1.pdf [accessed 2021-12-09]

17. Axelsson R, Axelsson SB. Integration and collaboration in public health—a conceptual framework. Int J Health Plann Manage 2006;21(1):75-88. [doi: 10.1002/hpm.826] [Medline: 16604850]

18. Tenti E, Casadei Gardini A, Schirone A, Passardi A, Minguzzi M, Prati E, et al. Medication reconciliation in cancer day hospital. JCO 2015 May 20;33(15_suppl):e17748-e17748. [doi: 10.1200/jco.2015.33.15_suppl.e17748]
19. Mekonnen AB, McLachlan AJ, Brien JAE. Effectiveness of pharmacist-led medication reconciliation programmes on clinical outcomes at hospital transitions: a systematic review and meta-analysis. BMJ Open 2016 Feb 23;6(2):e010003 [FREE Full text] [doi: 10.1136/bmjopen-2015-010003] [Medline: 26908524]

20. Mueller SK, Sponsler KC, Kripalani S, Schnipper JL. Hospital-based medication reconciliation practices: a systematic review. Arch Intern Med 2012 Jul 23;172(14):1057-1069 [FREE Full text] [doi: 10.1001/archinternmed.2012.2246] [Medline: 22733210]

21. Broadfield L, Shaheen P, Rogez M, Jamieson K, McCallum M. Guidelines for outpatient cancer care by community pharmacists. Can Pharm J (Ott) 2017;150(1):24-31 [FREE Full text] [doi: 10.1177/1715163516680009] [Medline: 28286590]

22. Mueller SK, Sponsler KC, Kripalani S, Schnipper JL. Hospital-based medication reconciliation practices: a systematic review. Arch Intern Med 2012 Jul 23;172(14):1057-1069 [FREE Full text] [doi: 10.1001/archinternmed.2012.2246] [Medline: 22733210]

23. Broadfield L, Shaheen P, Rogez M, Jamieson K, McCallum M. Guidelines for outpatient cancer care by community pharmacists. Can Pharm J (Ott) 2017;150(1):24-31 [FREE Full text] [doi: 10.1177/1715163516680009] [Medline: 28286590]

Abbreviations

AUSL: Azienda unità sanitaria locale
CP: community pharmacy
IRST: Istituto Romagnolo per lo Studio dei Tumori
IT: information technology
PROF: Progetto di Rete in Oncologia con le Farmacie di comunità della Romagna

©Alessandro Passardi, Patrizia Serra, Caterina Donati, Federica Fiori, Sabrina Prati, Roberto Vespignani, Gabriele Taglioni, Patrizia Farfanetti Ghetti, Giovanni Martinelli, Oriana Nanni, Mattia Altini, Giovanni Luca Frassineti, Martina Vittoria Minguzzi. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 20.12.2021. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research, is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.